Jane Street
STLN

Jane Street’s Starling Oncology STLN Stock Holding History

Jane Street’s Portfolio STLN Stock Details STLN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$237K Buy
+43,600
New +$183K ﹤0.01% 9724
2026
Q1 		– Sell
-13,100
Closed -$46.6K – 12992
2025
Q4 		$46.6K Buy
+13,100
New +$48.6K ﹤0.01% 10525

Other funds holding STLN

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
JAIC
Josh Arnold Investment Consultant Edina, Minnesota $159M AUM 142.62% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
WC
Wexford Capital West Palm Beach, Florida $782M AUM 62.56% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Nuveen
Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Jane Street's STLN Position: Q2 2026 in Review

Jane Street increased its Starling Oncology (STLN) stake by 101% in Q2 2026, buying an estimated $1.79M and bringing the position to 852,163 shares worth $4.63M. The position accounts for ﹤0.01% of the portfolio, ranked #3819.

Jane Street first reported a position in STLN in Q1 2023 and has held it in 10 quarters since. 119 funds tracked by Wall St. Rank hold STLN as of Q2 2026.

  • Jane Street held 852,163 shares of Starling Oncology worth $4.63M as of Q2 2026.
  • Jane Street bought 427,269 Starling Oncology shares in Q2 2026, an estimated $1.79M.
  • Starling Oncology made up ﹤0.01% of Jane Street's portfolio in Q2 2026, its #3819 holding.
  • Jane Street first reported a position in Starling Oncology in Q1 2023 and has held it in 10 quarters since.
  • 119 funds tracked by Wall St. Rank held Starling Oncology as of Q2 2026.

Based on Jane Street's 13F filing for Q2 2026, filed 14 Aug 2026.